NavDx®
Order Guide

NavDx®

Optimizing HPV+ Cancer Care

How to order

LOCAL BLOOD COLLECTION

For practices WITH blood collection capabilities

1. Order NavDx® test kits for delivery to your practice by emailing support@naveris.com or contacting your local representative
2. Complete the Test Request Form (TRF)
   - ☞ *If the selected billing type is "Insurance" or "Medicare," please submit a front and back copy of the patient's insurance or Medicare card, or the patient's face sheet, with the TRF*
   - ☞ *Ensure all Clinical Information fields are completed*
3. Apply the included patient label to the collection tube and complete the blood draw
4. Enclose sample and TRF in NavDx test kit and submit via FedEx

MOBILE BLOOD COLLECTION

For practices WITHOUT blood collection capabilities

Use our Mobile Phlebotomy Service for convenient, in-home blood collections:

1. Complete the TRF with *Mobile Blood Collection* selected, and fax to Naveris Client Services, 877-310-5073
   - ☞ *If the selected billing type is "Insurance" or "Medicare," please submit a front and back copy of the patient's insurance or Medicare card, or the patient's face sheet, with the TRF*
   - ☞ *Ensure all Clinical Information fields are completed*
2. Naveris Client Services will coordinate with patients to schedule blood collection at their convenience
3. Following blood collection, sample will be packaged in NavDx test kit and shipped via FedEx to Naveris

Ordering physicians will receive a NavDx Patient Report within 7 days from the date the Naveris lab receives the sample.

Sample requirements



- **Test sample:** One 10 mL tube of whole blood. Minimum sample required is 8 mL whole blood.
- **Storage and shipping:** Do not freeze or refrigerate. Ship same or next day at room temperature.

Note: NavDx® testing can be performed on diagnostic tumor tissue to confirm HPV status. Preferred sample is five, 5-µm formalin-fixed, paraffin-embedded sections, as curls or on unstained slides. Alternatively, a tissue block can be submitted and will be returned.

Testing with NavDx:

	RT ± CT	Surgery	Surgery followed by adjuvant RT ± CT	Neoadjuvant therapy followed by RT ± CT
Pretreatment	The patient's blood may be collected anytime prior to treatment, and at least 7 days after any biopsy procedure.			
During treatment	Test week 4 of RT Retest week 6 after RT	Test 2-3 weeks after surgery	Test 2-3 weeks after surgery Retest week 4 of RT Retest week 6 after RT	Test 2 weeks after neoadjuvant Retest week 4 of RT Retest week 6 after RT
Surveillance	1-3 years post treatment: test every 3 months 4-5 years post treatment: test every 6 months 6+ years post treatment: test 1 time per year			

RT = Radiation therapy
CT = Chemotherapy

NavDx®
Optimizing HPV+ Cancer Care

In the management of HPV+ head and neck cancer

Let their blood TTMV® guide you

NavDx® is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV) DNA blood test that aids in the detection of HPV-driven cancer.[1] NavDx lets you optimize the clinical management of HPV-driven cancer across the patient care continuum by confirming the HPV genotype, accurately assessing treatment response, identifying the presence of post-treatment molecular residual disease, and conveniently monitoring for recurrence.[1-3]

- Distinguish TTMV HPV DNA from non-cancerous sources of HPV DNA[2]
- Verify the presence of molecular residual disease post treatment, to identify and prioritize patients appropriate for adjuvant or follow-on chemoradiation treatment[1]
- Safely surveil based on highly accurate positive (94%) and negative (100%) predictive values for active HPV-driven malignancy[1]
- Accurately detect recurrence a median of 4 months earlier than it would present clinically via PET or CT scan to facilitate earlier initiation of salvage therapy[1]

If you have questions or would like additional information, contact us at **support@naveris.com** or **(833) 628-3747.**

References: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. *J Clin Oncol*. 2020;38(10):1050-1058. **2**. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. *Clin Cancer Res*. 2019;25(15):4682-4690. **3**. Head and neck cancers. Version 3.2021. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* 2021; https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.

NAVERIS

Naveris Inc., 22 Strathmore Road, Natick, MA 01760; contact@naveris.com; NavDx-0721-115

NavDx®

Optimizing HPV+ Cancer Care